The Patent Finder
GB

Generate Biomedicines, Inc.

First filing 2022
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Three patents currently held, every record listed here

5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in May 2043. from the record

Of the 5 now held by other companies, 5 were conveyed to Flagship Pioneering Innovations VI LLC in the filing they arrived in. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2043
Next term end
3
Patent families

When these terms end

Each bar runs from grant to computed term end. 2024 to 2044.
US 12,020,776 Optimizing Proteins Using Model Based Optimizations Apr 26, 2041
US 11,981,725 Antigen Binding Molecules Targeting SARS-CoV-2 Jul 6, 2041
US 11,987,616 Antigen Binding Molecules Targeting SARS-CoV-2 Aug 26, 2041
US 12,344,649 Modulators of Parathyroid Hormone Receptor (PTHR1) May 13, 2042
US 12,473,560 Antigen Binding Molecules Targeting SARS-CoV-2 Nov 20, 2042
US 11,993,644 Antigen Binding Molecules Targeting SARS-CoV-2 May 5, 2043
US 12,580,040 Diffusion Model for Generative Protein Design Nov 8, 2043
US 12,579,706 Image Generation with Flexible Sampler for Diffusion Modeling Jun 27, 2044
20282032203620402044
17 pending applications: term is not computable until grant.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 3 of 3

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,993,644Antigen Binding Molecules Targeting SARS-CoV-2
In force
 · High confidence
In forceHigh confidence
US 12,580,040Diffusion Model for Generative Protein Design
In force
 · Medium confidence
In forceMedium confidence
US 12,579,706Image Generation with Flexible Sampler for Diffusion Modeling
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 3: 5 patents in force now held by others · 17 applications pending · 5 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited